성심산학협력단

• 2024.05 | 공동저자 | BMJ SUPPORTIVE AND PALLIATIVE CARE, 제0권 0호, pp.0-0
  Haematological cancer versus solid tumour end-of-life care: a longitudinal data analysis
• 2024.04 | 교신저자 | INTERNATIONAL JOURNAL OF CARDIOLOGY, 제400권, pp.131786-131786
  Comparative efficacy of vericiguat to sacubitril/valsartan for patients with heart failure reduced ejection fraction: Systematic review and network meta-analysis
• 2024.03 | 제1저자 | AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 제24권 2호, pp.313-324
  Eligibility and Cost-Utility Analysis of Dapagliflozin in Patients with Heart Failure Across the Whole Spectrum of Ejection Fraction in South Korea
• 2024.02 | 교신저자 | VACCINE, 제42권 4호, pp.871-878
  Cost-effectiveness of the 20-valent pneumococcal conjugate vaccine versus the 23-valent pneumococcal polysaccharide vaccine for older adults in South Korea
• 2024.01 | 제1저자 | ESMO OPEN, 제9권 1호, pp.102200-102200
  Effectiveness of next-generation sequencing for patients with advanced non-small-cell lung cancer: a population-based registry study
• 2024.01 | 제1저자 | JOURNAL OF KOREAN MEDICAL SCIENCE, 제39권 1호, pp.8-8
  Real-World Eligibility and Cost-Effectiveness Analysis of Empagliflozin for Heart Failure in Korea
• 2023.12 | 제1저자 | DISASTER MEDICINE AND PUBLIC HEALTH PREPAREDNESS, 제17권
  Comparison of Perceived Importance and Performance of Community Pharmacists' Role in South Korea During the Coronavirus Disease 2019 Pandemic
• 2023.09 | 공동저자 | JOURNAL OF HOSPITAL INFECTION, 제139권, pp.249-250
  Impact of β-lactam allergies on antibiotic use, clinical outcomes, and economic costs in patients receiving surgical prophylactic antibiotics
• 2023.09 | 공동저자 | JOURNAL OF EVALUATION IN CLINICAL PRACTICE, 제29권 6호, pp.1016-1024
  Hospital outcomes and costs for prostate cancer patients with comorbid heart failure by age group: An analysis of the US Nationwide Inpatient Sample
• 2023.07 | 교신저자 | CLINICAL DRUG INVESTIGATION, 제43권 7호, pp.463-474
  Systematic Review of the Economic Evaluation of Sodium-Glucose Cotransporter-2 Inhibitors Used as Treatment in Patients with Heart Failure
• 2023.06 | 공동저자 | 약 학 회 지, 제67권 3호, pp.189-196
  건강보험청구자료를 이용한 HER2 양성 전이성 유방암 환자의 조기 사망에 따른 간접적 질병 부담 분석
• 2022.11 | 제1저자 | NICOTINE AND TOBACCO RESEARCH, 제24권 12호, pp.2011-2017
  Cost-Effectiveness Analysis of Smoking Cessation Interventions With Behavioral Support: A Study Based on the Benefits of Smoking Cessation on Outcomes (BENESCO) Model
• 2022.07 | 제1저자 | EXPERT OPINION ON PHARMACOTHERAPY, 제23권 11호, pp.1247-1257
  A systematic review of economic evaluations of tyrosine kinase inhibitors for non-small cell lung cancer (NSCLC)
• 2022.05 | 공동저자 | QUALITY OF LIFE RESEARCH, 제31권 5호, pp.1345-1357
  Health-related quality of life among elderly breast cancer patients treated with adjuvant endocrine therapy: a U.S Medicare population-based study
• 2021.12 | 공동저자 | CURRENT MEDICAL RESEARCH AND OPINION, 제37권 12호, pp.2043-2047
  In-hospital mortality, length of stay and hospital costs for hospitalized breast cancer patients with comorbid heart failure in the USA
• 2021.06 | 제1저자 | AMERICAN JOURNAL OF MANAGED CARE, 제27권 6호, pp.E181-+
  Hospital Outcomes of Male Breast Cancer in the United States
• 2021.05 | 공동저자 | EXPERT REVIEW OF PHARMACOECONOMICS AND OUTCOMES RESEARCH, 제21권 3호, pp.381-393
  Cost-effectiveness analyses of targeted therapy and immunotherapy for advanced non-small cell lung cancer in the United States: a systematic review
• 2021.05 | 제1저자 | EXPERT REVIEW OF PHARMACOECONOMICS AND OUTCOMES RESEARCH, 제21권 3호, pp.395-402
  Association of congestive heart failure with hospital outcomes among renal cancer patients in the United States: analysis of nationwide inpatient sample
• 2021.02 | 공동저자 | JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 제46권 1호, pp.35-49
  A network meta-analysis of efficacy and safety of first-line and second-line therapies for the management of metastatic renal cell carcinoma
• 2020.12 | 공동저자 | JOURNAL OF EVALUATION IN CLINICAL PRACTICE, 제26권 6호, pp.1677-1688
  Association of depression with adherence to breast cancer screening among women aged 50 to 74 years in the United States
• 2020.11 | 교신저자 | CURRENT MEDICAL RESEARCH AND OPINION, 제36권 11호, pp.1825-1833
  The economic impact of disease progression and death in hormone receptor positive (HR plus ), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer patients: using Korean nationwide health insurance claims data
• 2019.12 | 제1저자 | JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 제34권 12호, pp.2135-2143
  Beyond uncertainty: Negative findings for the association between the use of proton pump inhibitors and risk of dementia
• 2019.11 | 제1저자 | EXPERT REVIEW OF PHARMACOECONOMICS AND OUTCOMES RESEARCH, 제19권 6호, pp.633-643
  Economic evaluations of oral medications for breast cancer treatment in the US: a systematic review with a focus on cost-effectiveness threshold
• 2019.11 | 공동저자 | JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY: IN PRACTICE, 제7권 8호, pp.2642-2642
  A Comparison of Leukotriene Receptor Antagonists to Low-Dose Inhaled Corticosteroids in the Elderly with Mild Asthma
• 2019.06 | 제1저자 | CLINICAL THERAPEUTICS, 제41권 6호, pp.1066-1079
  Cost-Utility Analysis of Sacubitril/Valsartan Use Compared With Standard Care in Chronic Heart Failure Patients With Reduced Ejection Fraction in South Korea
• 2018.08 | 공동저자 | CLINICAL DRUG INVESTIGATION, 제38권 8호, pp.727-736
  The Utility of 5 Hypothetical Health States in Heart Failure Using Time Trade-Off (TTO) and EQ-5D-5L in Korea
• 2018.06 | 제1저자 | DRUG SAFETY, 제41권 6호, pp.615-624
  The Uncertainty of the Association Between Proton Pump Inhibitor Use and the Risk of Dementia: Prescription Sequence Symmetry Analysis Using a Korean Healthcare Database Between 2002 and 2013
• 2017.01 | 제1저자 | CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 제35권, pp.689-699
  A comparison of discontinuation rates of tofacitinib and biologic disease-modifying anti-rheumatic drugs in rheumatoid arthritis: a systematic review and Bayesian network meta-analysis regression
• 2017.01 | 공동저자 | EXPERT REVIEW OF PHARMACOECONOMICS AND OUTCOMES RESEARCH, 제17권 4호, pp.411-419
  Eliciting societal preferences of reimbursement decision criteria for anti cancer drugs in South Korea
• 2016.11 | 제1저자 | CLINICAL THERAPEUTICS, 제37권 11호, pp.2430-2446
  Cost-effectiveness Analysis of Treatment Sequence Initiating With Etanercept Compared With Leflunomide in Rheumatoid Arthritis: Impact of Reduced Etanercept Cost With Patent Expiration in South Korea
• 2015.08 | 공동저자 | CLINICAL THERAPEUTICS, 제37권 8호, pp.1662-1676
  Cost-effectiveness of Tofacitinib in the Treatment of Moderate to Severe Rheumatoid Arthritis in South Korea
• 2015.03 | 제1저자 | 한국임상약학회지, 제25권 1호, pp.9-17
  Conventional DMARDs 치료에 실패한 류마티스 관절염 환자에서 Biologic DMARDs의 임상적 효과 비교: 베이지안 네트워크 메타분석
• 2014.05 | 공동저자 | ARCHIVES OF PHARMACAL RESEARCH, 제37권, pp.662-670
  Comparative effectiveness of cycling of tumor necrosis factor-alpha (TNF-alpha) inhibitors versus switching to non-TNF biologics in rheumatoid arthritis patients with inadequate response to TNF-alpha inhibitor using a Bayesian approach

• 2023.09 | 공동 | 범문에듀케이션
  약무행정과 경영관리
• 2023.03 | 공동 | 자유아카데미
  보건의료 빅데이터 연구방법론 : 국내 보건의료 빅데이터 활용 연구방법부터 머신러닝 분석까지
• 2022.09 | 공동 | 범문에듀케이션
  약사윤리학

산업과제
2021년 심부전에서의 OOO의 경제성평가(한국OOO제약)
2021년 ATTR-CM 환자 진단에서 심내막심근생검 대비 scintigraphy의 경제성평가(한국OOO제약)
2021년 아토피 치료에 대한 OOO의 간접비교(한국OOO제약)
2021년 아토피 치료에서 OOO 사용에 대한 재정영향분석(한국OOO제약)
2022년 OOOO 백신접종에 대한 경제성평가(한국OOO제약)
2024년 OOOO의 경제성평가(한국OOO제약)